Regeneron Pharmaceuticals, Inc.

Company facts

Industry

Pharmaceutical Preparations

Headquarters

Tarrytown, New York

Most recent report

10-Q, filed Oct 30, 2026

Incorporated

New York

Filings on record

1,000+ filings

On EDGAR

CIK 872589

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Sep 2026 10-Q

SECSift found 3 of 11 sections worth reading, with 0 positive, 11 notable, and 7 negative flags.

• Financial Statements (Item 1)

  Financial statements and notes with key balance-sheet swings, litigation, and a major collaboration amendment.
  Notable

  • Sanofi amendment adds four antibodies; Regeneron received $1.0B up-front payment in October 2026.
  • Multiple patent lawsuits over EYLEA and EYLEA HD biosimilars ongoing; some settlements reached.
  • Jury awarded Regeneron $135.6M compensatory and $271.2M punitive damages against Amgen for Praluent anticompetitive conduct.
  • DOJ civil complaint and qui tam actions allege Anti-Kickback Statute violations; court denied motion to dismiss in April 2025.

• Management's Discussion (Item 2)

  Full MD&A with detailed product sales, pipeline, and financial results.
  Notable

  • Fianlimab Phase 3 in first-line metastatic melanoma did not reach statistical significance for primary endpoint.
  • Discontinued itepekimab in COPD, CRSwNP, and CRSsNP; also discontinued birch allergy and beta-thalassemia programs.
  • U.S. government agreements cap prices at Most-Favored-Nation pricing; Otarmeni given free in U.S.
  • Board authorized $3.0B share repurchase in April 2026; $2.157B remained at Sept 30, 2026.
  • Quarterly dividend of $0.94 per share declared in Q1-Q3 2026 and again in October 2026.

• Risk Factors (Item 1A)

  Company-specific revenue concentration, biosimilar erosion, and FDA delays quantified.
  Notable

  • Company entered U.S. Government Agreements in April 2026, capping prices at Most-Favored-Nation levels and exempting from Section 232 tariffs through Jan 2029.
  • Class A stockholders hold 15.2% of voting power; top 5 shareholders + CEO hold 31.3% of common stock and 40.0% of voting power.
  Negative

  • EYLEA HD and EYLEA combined were 23% of total revenue in 9M 2026, down from 32% in 9M 2025.
  • EYLEA U.S. net sales fell 41% in Q3 and 9M 2026 vs. 2025 due to biosimilar competition.
  • Sanofi collaboration revenue (mostly Dupixent) was 50% of total revenue in 9M 2026, up from 41% in 9M 2025.
  • Two distributor customers accounted for 77% of total gross product revenue in 9M 2026 and 2025.
  • A Phase 3 trial for fianlimab + Libtayo in first-line metastatic melanoma failed to meet its primary endpoint in May 2026.
  • Bulk manufacturing at Limerick, Ireland was temporarily interrupted in Q1-Q2 2026 due to unanticipated facility repairs.
  • A putative securities class action was filed against the company in July 2026.

What changed: Sep 2026 vs. Jun 2026

About 5% of REGN's Sep 2026 10-Q is new information. 33 paragraphs were added, 164 changed, and 36 removed. Below are the most important lines SECSift identified.

• Item 1 61
• Item 2 57
• Item 1A 35
• Item 5 1
• Item 3 1
• Item 4 1
• Item 6 1